Objectives: To describe wild-type distributions of the MIC of fluoroquinolones for Mycobacterium tuberculosis in relation to current critical concentrations used for drug susceptibility testing and pharmacokinetic/ pharmacodynamic (PK/PD) data.
Introduction
In light of the increasing prevalence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB), accurate and reproducible antimicrobial susceptibility testing (AST) has become increasingly important. Today, AST of Mycobacterium tuberculosis is based on using single so-called critical concentrations defined as 'the lowest concentration of drug that will inhibit 95% (90% for pyrazinamide) of wild strains of M. tuberculosis that have never been exposed to drugs, while at the same time not inhibiting clinical strains of M. tuberculosis that are considered to be resistant (e.g. from patients who are not responding to therapy)'. 1, 2 Apart from the problematic fact that this definition automatically makes 5% of presumably susceptible strains resistant, the recommended critical concentrations 3 for many second-line drugs are to a large extent based on consensus rather than scientific evidence. Using inadequate susceptibility breakpoints might lead to poor reproducibility and erroneous results that could jeopardize effective antimicrobial therapy and lead to confusing reporting of AST results to clinicians. The limited scientific background for the critical concentrations used for the second-line drugs is especially problematic, a fact that has been acknowledged by the WHO. 1 We have previously described the very narrow corridor between the wild-type MIC distribution and the critical concentration for ethambutol as an example of a problematic clinical breakpoint causing reproducibility problems. 4 For other bacterial pathogens, the use of wild-type MIC distributions has become a necessary and widely used tool in the armamentarium of instruments for determining clinical breakpoints. A bacterial isolate is defined as a wild-type if it has no acquired and mutational resistance mechanisms against a certain drug. Such an isolate will invariably have an MIC that belongs to the normal distribution when testing MICs for many isolates. On the other hand, an isolate for which the MIC is outside the normal distribution-or the wild-type distributionwill most likely harbour resistance mechanisms. The wild-type cut-off, commonly labelled the epidemiological cut-off (ECOFF) value, is, together with pharmacokinetic/pharmacodynamic (PK/PD) and clinical data, used by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) when determining clinical breakpoints. 5 The clinical breakpoint may be higher than the ECOFF if it is proved that strains with higher MICs are still treatable with standard dosages. However, clinical outcome data in relation to MIC values of individual drugs are very difficult, if at all possible, to obtain for second-line drugs for MDR TB where several drugs are used in various combinations according to standardized treatment protocols or as susceptibility pattern guided therapy. As a result, the best available alternative in order to establish reasonable clinical breakpoints for M. tuberculosis is probably to define wild-type MIC distributions and their ECOFFs and relate these to PK/PD data.
Wild-type MIC distributions and ECOFFs can also be used to detect low-level resistance in isolates, which might still be treatable with increased dosing. For example, some clinicians empirically use higher daily doses of isoniazid in the face of low-level resistance and although clinical outcome data are scarce, this is supported by PK/PD calculations showing that non-wild-type isolates for which the MICs are relatively low are at least theoretically available for treatment with a high-dosage regimen. 4 Monitoring such low-level resistance would also be important for the early detection of drug resistance and for the discovery of new genetic resistance mechanisms that may then be included in genotypic susceptibility testing. Surprisingly, reports on wildtype MIC distributions for M. tuberculosis, requested by many experts, 6 -8 are scarce or absent, probably due to the complexity of the AST methods used today.
Fluoroquinolones are gyrase-inhibiting nalidixic acid derivatives that have broad-spectrum antibacterial activity and have been used in anti-TB treatment since the late 1980s. Fluoroquinolones are, together with injectable drugs (such as aminoglycosides), the most important group of second-line drugs against TB. Representatives of both of these groups should be used in combination with three oral agents for at least 18 months in the treatment of MDR TB. 1 Agents of the new class of fluoroquinolones, moxifloxacin and levofloxacin, are regarded to have a better clinical efficacy compared with ciprofloxacin and ofloxacin, 1 although poor availability in high endemic areas might limit their use. Moxifloxacin is currently undergoing phase III trials in Kenya, Tanzania, Zambia and South Africa. 9 We have shown previously that wild-type MIC distributions can be established for the first-line drugs isoniazid, rifampicin and ethambutol, and that the current critical concentrations may be re-evaluated based on these data. 4 Since the scientific basis for susceptibility breakpoints against second-line drugs is weak, the objectives of the present study are: (i) to establish wildtype MIC distributions and ECOFFs for fluoroquinolones, an important class of second-line drugs against TB; (ii) to compare these data with the currently recommended critical concentrations; and (iii) to discuss the possible need to set alternative clinical breakpoints by combining our knowledge of wild-type MIC distributions and ECOFFs with that of PK and PD data.
Methods

Strains
In two rounds we tested 90 consecutive clinical strains of M. tuberculosis from the Karolinska University Hospital Mycobacteriology Laboratory. Moreover, we tested 24 non-consecutive strains including 8 isolates with known drug resistance from the same laboratory, and 16 strains selected from the WHO's external quality assessment (EQA) panels. 10 The consecutive strains represented a heterogeneous collection as at least 78% of patients with TB in Sweden are foreign born, predominantly originating from high endemic areas. 11 All strains had a unique restriction fragment length polymorphism (RFLP) pattern determined by the Swedish Institute for Infectious Disease Control.
Quality control
M. tuberculosis H37Rv (ATCC 27249) was tested in duplicate in both rounds. Another fully susceptible strain from the consecutive collection was tested once in each round and five strains from the EQA panels were tested in duplicate in the second round. In addition, we tested three consecutive isolates from the same patient isolated within a year of ongoing therapy for MDR TB.
Antimicrobial susceptibility testing
The susceptibilities of all isolates to the first-line drugs (i.e. rifampicin, isoniazid, ethambutol and pyrazinamide) had been determined previously with the BACTEC 460 method (B460) (BD, Sparks, MD, USA). Susceptibility to ofloxacin (2.0 mg/L) had been tested on 11 consecutive isolates that were resistant to one or more first-line drugs, and to 19 non-consecutive isolates. Susceptibility to moxifloxacin (0.5 mg/L) had been determined for four isolates.
MIC determinations
The methodology has been described in detail previously. 4 Stock solutions (30.7 g/L) were prepared for ciprofloxacin (Fluka) in 0.1 M HCl, ofloxacin (Sigma) in 0.2 M NaOH, moxifloxacin in 0.1 M NaOH (Bayer) and levofloxacin (Fluka) in DMSO (Sigma). Briefly, bacterial suspensions diluted to the turbidity of 0.5 McFarland of all strains were transferred by using a 96-stick replicator to Middlebrook 7H10 agar plates with serial 2-fold dilutions from 0.002 to 512 mg/L for all drugs. Drug-free control plates with undiluted and 1:100 diluted suspensions were replicated in the same way and the plates were incubated at 378C for 3 weeks. The MIC was defined as the first antibiotic concentration where there was less growth compared with the 1:100 diluted controls MIC distributions of fluoroquinolones for M. tuberculosis 947 JAC of the corresponding strain, i.e. the lowest concentration of drug that inhibited .99% of the bacterial population.
MIC testing in BACTEC MGIT 960 (MGIT) (BD) was performed on a subset of 12 strains. Each strain was tested against five serial 2-fold dilutions of ofloxacin (prepared as above) and diluted to final concentrations corresponding to two MIC steps above and below the MIC obtained in the Middlebrook 7H10 experiment. M. tuberculosis H37Rv was included in all runs as a quality control strain.
PK/PD calculations
Area under the curve over MIC (AUC/MIC) was calculated for ciprofloxacin, ofloxacin, levofloxacin and moxifloxacin. Standard dosages of these drugs as recommended by the WHO were included. 3 The free fraction was calculated by multiplying the percentage of protein-free drug fraction with AUC and the free fractions of this variable (fAUC) were then divided with the corresponding MIC value. The PK data used for calculations are presented in Table 3 . All parameters were used in the lower range from previously published data, to encompass individual variation.
12,13
Results
MIC determinations on Middlebrook 7H10 medium were reproducible
Overall, the MIC variation within and between runs was within+ one 2-fold dilution step (Table 1) . M. tuberculosis H37Rv was tested four times and seven strains including resistant and susceptible strains from the EQA panel were tested twice. For ofloxacin and levofloxacin, the MICs were identical at all test occasions while the MIC differed one dilution step from the modal MIC at three and two occasions for ciprofloxacin and moxifloxacin, respectively. Three isolates of the same strain coming from an MDR patient undergoing treatment showed identical MICs of levofloxacin and ofloxacin, while for both ciprofloxacin and moxifloxacin there was one deviation from the modal MIC.
MIC distributions clearly separated wild-type and non-wild-type strains
For the four studied fluoroquinolones, the MICs for the 90 consecutive clinical isolates formed a Gaussian shaped distribution-the wild-type MIC distribution (Figure 1a-d and Table 3 ). The ECOFFs (i.e. the highest MIC within the wild-type) were found to be S (susceptible)≤ 1.0 mg/L for ciprofloxacin and ofloxacin, and S≤ 0.5 mg/L for moxifloxacin and levofloxacin. The wild-type isolates were all classified as susceptible when applying WHO's recommended critical concentrations (S≤ 2.0 mg/L) 3 for ciprofloxacin, ofloxacin and levofloxacin. For moxifloxacin, there is not yet any recommended critical concentration for testing on solid medium but the recommended critical concentrations for MGIT and B460 are 0.25 and 0.5 mg/L, respectively.
3 Among the 24 non-consecutive strains, 2 had MICs distinctly higher than the ECOFF. When applying WHO's critical concentrations (S≤ 2.0 mg/L), 3 these two isolates were classified as resistant to ofloxacin in agreement with consensus results of WHO's EQA panel ( Table 2 ) but one of the strains was doubtfully classified as susceptible to ciprofloxacin and levofloxacin which is most likely an artefact of the current critical concentrations (Figure 1a and d) .
MIC results were confirmed in a subset of strains using BACTEC MGIT 960 and BACTEC 460
Two strains for which the MICs were above the ECOFF had previously been classified as resistant to ofloxacin at 2.0 mg/L with the B460 which was confirmed by determining the MIC with the MGIT method ( Table 2 ). For 2 resistant and 10 susceptible strains there was an excellent agreement in MIC levels comparing 7H10 with MGIT. Drug susceptibility results of these strains were also in agreement with the B460 results and the consensus results of the EQA panel (if applicable) ( Table 2) . Among strains for which fluoroquinolone MICs were equal to or below the ECOFFs and categorized as susceptible with 7H10 critical concentrations, 11 consecutive and 19 non-consecutive had been tested susceptible to ofloxacin 2.0 mg/L and four had been tested susceptible to moxifloxacin 0.5 mg/L using B460.
fAUC/MIC ratios of the wild-type strains were more favourable for levofloxacin and moxifloxacin compared with ofloxacin and ciprofloxacin
The results of the PK/PD calculations are shown in Table 3 . For the investigated doses, PD indices (fAUC/MIC) were most Ä ngeby et al.
favourable for levofloxacin followed by moxifloxacin, both covering the majority of the wild-type at a higher fAUC/MIC ratio than ofloxacin, followed by ciprofloxacin (Table 3) . For the MICs at the current critical concentrations where an isolate is classified as susceptible to ciprofloxacin, ofloxacin and levofloxacin, the calculated fAUC/MIC was in the range 14 -23 (Table 3) .
Discussion
Fluoroquinolones are essential in the treatment of MDR TB, and fluoroquinolone resistance together with resistance to one or more injectable drugs constitutes the definition of XDR TB. Thus, a very careful determination of clinical breakpoints based on solid background data is warranted. Unfortunately, the Consecutive susceptible clinical isolates indicated by black bars (n¼90) were used to define the wild-type MIC distributions for ciprofloxacin, ofloxacin, moxifloxacin and levofloxacin. The wild-type cut-offs, also designated the ECOFFs, are indicated by arrows. The MICs for the non-consecutive isolates (resistant to any drug) identified by white bars (n¼24) with two exceptions closely follow the wild-type distribution indicating that they are also wild-type regarding fluoroquinolone susceptibility. Two isolates have MICs above the ECOFF indicating that they have resistance mechanisms against fluoroquinolones, which was further underlined by cross-resistance to ofloxacin where results were in consensus with EQA results. One of these isolates would have been defined as susceptible to ciprofloxacin and levofloxacin using the current critical concentrations, which are pointed out by arrows.
recommended critical concentrations as of today are based on limited scientific grounds. The complexity of current regimens against MDR TB makes it very difficult to evaluate clinical outcome data against the MIC level of a single drug. Thus, the major tools at hand to determine clinical breakpoints for susceptibility testing are wild-type MIC distributions and PK/PD calculations.
Using a highly reproducible high-throughput method we could readily obtain wild-type MIC distributions for the major fluoroquinolones. Our MIC values are in agreement with several previous reports including some with limited numbers of non-consecutive strains with often insufficient MIC levels in the lower range of the wild-type. 7,8,14 -16 For a proportion of both susceptible and resistant strains in the EQA panel we showed excellent agreement with BACTEC 460 and BACTEC 960 MGIT. Based on the data on consecutive strains shown in Figure 1(a-d) , we suggest tentative ECOFFs of S≤ 1.0 for ciprofloxacin and ofloxacin and S≤ 0.5 mg/L for moxifloxacin and levofloxacin. Experience from other bacteria suggest that with a standardized methodology the typical base of a wild-type MIC distribution is 3 -5 dilution steps, for fluoroquinolones most often 4 or 5 dilution steps. It is possible that the ECOFFs of ofloxacin and levofloxacin could be adjusted to 2.0 (rather than 1.0) and 1.0 (instead of 0.5) mg/L, respectively, if a larger number of isolates were tested in several laboratories. The three isolates that had a ciprofloxacin MIC of 1 mg/L, and the single isolate that had a moxifloxacin MIC of 0.5 mg/L, exhibited wild-type MICs to the other fluoroquinolones and were susceptible to all first-line TB drugs (data not shown). Thus, they are unlikely to harbour any acquired or mutational resistance mechanisms that would define them as non-wild-type according to the EUCAST definitions. 5 The tentative ECOFFs are lower than the recommended critical concentrations (S≤ 2.0 mg/L) for Middlebrook 7H10 medium for ciprofloxacin, ofloxacin and levofloxacin, whereas for moxifloxacin the WHO has not yet recommended any critical concentration. The problems with the current breakpoints are underscored by the fact that one strain previously classified as resistant to ofloxacin in the EQA panel with MICs clearly above the ECOFF for all tested fluoroquinolones would have been classified as susceptible to levofloxacin and ciprofloxacin using the current critical concentrations.
In recent validations of new methods, such as MGIT, the determination of the new critical concentrations is based on comparisons with the critical concentration used with a reference method (B460 or agar proportion method). In those evaluations no thorough investigation of the suitability of the breakpoint itself was made but rather MIC determinations at concentrations close to the old critical concentration. 17 -19 This might lead to reproducibility problems if the new breakpoint is adjusted to become very close to or even splitting the wild-type distribution.
No PD target has been defined for M. tuberculosis, and the PK/ PD data in relation to the wild-type MIC distributions must therefore be interpreted carefully. In general, the fAUC/MIC ratio for the wild-type had the highest value for levofloxacin followed by moxifloxacin, ofloxacin and ciprofloxacin (Table 3) . Using the PD target of 40 that has been suggested for Gram-positive organisms, 12, 20 the majority of the wild-type was covered for all tested fluoroquinolones, whereas if the Gram-negative target of 80 -120 12, 20 was applied, only the wild-type of levofloxacin would be fully covered. However, one cannot argue that either target is more adequate. Rather the target for M. tuberculosis should be determined in clinical studies, but it is difficult to study the outcome of single drugs during combination therapy. Studies of early bactericidal activity (EBA) have recently Ä ngeby et al.
been reviewed, 21 and show that all the fluoroquinolones that are included in our paper have an EBA during the first 2 days of treatment similar to that of isoniazid. However, EBA (defined as the mean fall in colony counts in sputum per day during 2 days of treatment) has been reported to be lowest for ciprofloxacin (0.21), followed by ofloxacin (0.32-0.38), moxifloxacin (0.33 -0.53) and levofloxacin (0.45). Although these data (with one exception) have been obtained in different studies, they seemingly parallel our findings. As a comparison, the EBA after 2 days of treatment with isoniazid was reported to be 0.37-0.77. In only one study, 22 have two quinolones been compared head to head showing a higher EBA for levofloxacin 1000 mg/day (0.45) than for moxifloxacin 400 mg/day (0.38). Even if this difference was not statistically significant, the EBA for moxifloxacin was significantly lower than that for isoniazid (0.67) (P,0.05) but the EBA for levofloxacin was not. Although EBA can only study the ability of single drugs to kill metabolically active bacteria during a few days of monotherapy, these data as well as ours support the use of the newer fluoroquinolones levofloxacin and moxifloxacin rather than ofloxacin and in particular ciprofloxacin. However, clinical trials on the role of fluoroquinolones in the multidrug treatment of TB are under way and should be considered in this context.
In concordance with our results, the WHO guidelines no longer recommend ciprofloxacin for treatment of TB and ofloxacin is only recommended as an acceptable alternative if newer fluoroquinolones cannot be afforded. 1 It is interesting to note that although several authors report and underscore that moxifloxacin has the lowest MIC values in the quinolone group, the fAUC is also considerably lower than that for levofloxacin clearly illustrating the need to integrate PK/PD calculations, MIC determinations and clinical outcome data where available when discussing efficacy and MIC levels of antimicrobial agents.
In conclusion, based on the wild-type MIC distributions, we suggest S≤ 1.0 mg/L as a tentative ECOFF for ciprofloxacin and ofloxacin and S≤ 0.5 as a tentative ECOFF for levofloxacin and moxifloxacin for testing at Middlebrook 7H10 agar. Taking into account that (i) the current critical concentrations are based neither on clinical outcome data analysis, nor on any PD model, and (ii) that the fAUC is very low (ranging from 14 to 23) ( Table 3) for MIC values equal to the current critical concentration of S≤ 2.0 mg/L for ciprofloxacin, ofloxacin and levofloxacin, it seems reasonable to consider using the suggested ECOFFs as clinical breakpoints for all three and for moxifloxacin which has no official breakpoint as yet. The use of ofloxacin and even more so ciprofloxacin should be avoided if newer fluoroquinolones are affordable. Further studies are needed to define suitable PD targets and to confirm the wild-type MIC distribution data including routine methods such as BACTEC MGIT 960 for M. tuberculosis.
